B
41.73
1.73 (4.32%)
| Previous Close | 40.00 |
| Open | 40.41 |
| Volume | 5,525,089 |
| Avg. Volume (3M) | 2,935,859 |
| Market Cap | 7,923,733,504 |
| Price / Sales | 64.03 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 76.00 (Wells Fargo, 82.12%) | Buy |
| Median | 56.00 (34.20%) | |
| Low | 49.00 (Wolfe Research, 17.42%) | Buy |
| Average | 60.71 (45.48%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 40.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 30 Jun 2025 | 76.00 (82.12%) | Buy | 43.18 |
| B of A Securities | 25 Jun 2025 | 54.00 (29.40%) | Buy | 44.38 |
| Wolfe Research | 17 Jun 2025 | 49.00 (17.42%) | Buy | 40.07 |
| HC Wainwright & Co. | 09 Jun 2025 | 56.00 (34.20%) | Buy | 39.03 |
| 15 Apr 2025 | 53.00 (27.01%) | Buy | 34.24 | |
| Piper Sandler | 30 Apr 2025 | 63.00 (50.97%) | Buy | 38.36 |
| Scotiabank | 30 Apr 2025 | 55.00 (31.80%) | Buy | 38.36 |
| UBS | 30 Apr 2025 | 72.00 (72.54%) | Buy | 38.36 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AGUIAR ERIC | 41.73 | - | 6,589 | 274,959 |
| COOK JENNIFER E. | 41.73 | - | 6,589 | 274,959 |
| DACHILLE DOUGLAS A. | 41.73 | - | 6,589 | 274,959 |
| DANIELS RONALD J | 41.73 | - | 6,589 | 274,959 |
| ELLIS ANDREA | 41.73 | - | 6,589 | 274,959 |
| HASSAN FRED | 41.73 | - | 6,589 | 274,959 |
| HOMCY CHARLES J | 41.73 | 44.86 | -13,411 | -622,241 |
| LO ANDREW | 41.73 | - | 6,589 | 274,959 |
| MCCORMICK FRANK | 41.73 | 44.45 | -93,411 | -4,170,041 |
| MOMTAZEE JAMES C | 41.73 | - | 6,589 | 274,959 |
| SATVAT ALI J. | 41.73 | - | 6,589 | 274,959 |
| SCOTT RANDAL W. | 41.73 | - | 6,589 | 274,959 |
| VALANTINE HANNAH | 41.73 | 45.12 | 1,882 | 62,579 |
| Aggregate Net Quantity | -39,050 | |||
| Aggregate Net Value ($) | -1,980,113 | |||
| Aggregate Avg. Buy ($) | 41.73 | |||
| Aggregate Avg. Sell ($) | 44.89 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOMCY CHARLES J | Director | 27 Jun 2025 | Disposed (-) | 20,000 | 44.86 | 897,200 |
| VALANTINE HANNAH | Director | 26 Jun 2025 | Sell (-) | 2,418 | 45.12 | 109,100 |
| VALANTINE HANNAH | Director | 26 Jun 2025 | Sell (-) | 2,289 | 45.12 | 103,280 |
| MCCORMICK FRANK | Director | 24 Jun 2025 | Automatic sell (-) | 100,000 | 44.45 | 4,445,000 |
| SCOTT RANDAL W. | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| VALANTINE HANNAH | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| DACHILLE DOUGLAS A. | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| HASSAN FRED | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| HOMCY CHARLES J | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| MOMTAZEE JAMES C | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| SATVAT ALI J. | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| DANIELS RONALD J | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| AGUIAR ERIC | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| MCCORMICK FRANK | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| COOK JENNIFER E. | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| ELLIS ANDREA | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| LO ANDREW | Director | 20 Jun 2025 | Acquired (+) | 6,589 | 41.73 | 274,959 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |